Skip to main content
Erschienen in: Uro-News 11/2018

29.10.2018 | Prostatakarzinom | Zertifizierte Fortbildung

Standardisierte Einschätzung

Entscheidungshilfen für die Diagnostik und Therapie des Prostatakarzinoms

verfasst von: Jessica Rührup, Dr. med. Felix Preisser, Lena Theissen, Philipp Mandel, Felix K. -H. Chun

Erschienen in: Uro-News | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Entscheidungen zur Behandlung von Prostatakarzinompatienten basieren immer noch oft auf der individuellen Erfahrung des behandelnden Arztes. Diese variiert jedoch stark. Um Erfahrungsunterschiede auszugleichen und Ärzte in der genauen Einschätzung des Tumorstadiums und der Prognose des Patienten zu unterstützen, können klinische Hilfsmittel zur Planung von Diagnostik und Therapie eingesetzt werden.
Literatur
1.
Zurück zum Zitat Specht MC et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005; 12:654–9.CrossRef Specht MC et al. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005; 12:654–9.CrossRef
2.
Zurück zum Zitat Chun FK et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol. 2007;52:436–44CrossRef Chun FK et al. Development and external validation of an extended 10-core biopsy nomogram. Eur Urol. 2007;52:436–44CrossRef
3.
Zurück zum Zitat Karakiewicz PI et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005;173:1930–4CrossRef Karakiewicz PI et al. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005;173:1930–4CrossRef
4.
Zurück zum Zitat De Nunzio C et al. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort- study. Urol Oncol. 2018;36:364, e361-364, e367CrossRef De Nunzio C et al. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort- study. Urol Oncol. 2018;36:364, e361-364, e367CrossRef
5.
Zurück zum Zitat Auprich M et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol. 2010;58:727–32CrossRef Auprich M et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol. 2010;58:727–32CrossRef
6.
Zurück zum Zitat Chun FK et al. Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007;177:510–5CrossRef Chun FK et al. Development and external validation of an extended repeat biopsy nomogram. J Urol. 2007;177:510–5CrossRef
7.
Zurück zum Zitat Walz J et al. A nomogram predicting 10- year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25:3576–81CrossRef Walz J et al. A nomogram predicting 10- year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol. 2007; 25:3576–81CrossRef
8.
Zurück zum Zitat Mottet N et al. EAU — ESTRO — ESUR — SIOG Guidelines on Prostate Cancer. 2018. Mottet N et al. EAU — ESTRO — ESUR — SIOG Guidelines on Prostate Cancer. 2018.
9.
Zurück zum Zitat Partin AW et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–4CrossRef Partin AW et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–4CrossRef
10.
Zurück zum Zitat Leyh-Bannurah SR et al. Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate. 2017;77:105–13CrossRef Leyh-Bannurah SR et al. Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. Prostate. 2017;77:105–13CrossRef
11.
Zurück zum Zitat Graefen M et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol. 2003;43:6–10CrossRef Graefen M et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol. 2003;43:6–10CrossRef
12.
Zurück zum Zitat Augustin H et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol. 2004;171:177–81CrossRef Augustin H et al. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer. J Urol. 2004;171:177–81CrossRef
13.
Zurück zum Zitat Briganti A et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480–7CrossRef Briganti A et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480–7CrossRef
14.
Zurück zum Zitat Hansen J et al. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate. 2013;73:211–8CrossRef Hansen J et al. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. Prostate. 2013;73:211–8CrossRef
15.
Zurück zum Zitat Graefen M et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol. 2001;165:857–63CrossRef Graefen M et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol. 2001;165:857–63CrossRef
16.
Zurück zum Zitat Steuber T et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006;175(3 Pt 1):939–44CrossRef Steuber T et al. Validation of a nomogram for prediction of side specific extracapsular extension at radical prostatectomy. J Urol. 2006;175(3 Pt 1):939–44CrossRef
17.
Zurück zum Zitat Zorn KC et al. External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J Endourol. 2007;21:1345–51CrossRef Zorn KC et al. External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy. J Endourol. 2007;21:1345–51CrossRef
18.
Zurück zum Zitat Lughezzani G et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58:687–700CrossRef Lughezzani G et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol. 2010;58:687–700CrossRef
19.
Zurück zum Zitat Kattan MW et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–507CrossRef Kattan MW et al. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–507CrossRef
20.
Zurück zum Zitat Kattan MW et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000; 18:3352–9CrossRef Kattan MW et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000; 18:3352–9CrossRef
Metadaten
Titel
Standardisierte Einschätzung
Entscheidungshilfen für die Diagnostik und Therapie des Prostatakarzinoms
verfasst von
Jessica Rührup
Dr. med. Felix Preisser
Lena Theissen
Philipp Mandel
Felix K. -H. Chun
Publikationsdatum
29.10.2018
Verlag
Springer Medizin
Erschienen in
Uro-News / Ausgabe 11/2018
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676
DOI
https://doi.org/10.1007/s00092-018-1689-5

Weitere Artikel der Ausgabe 11/2018

Uro-News 11/2018 Zur Ausgabe